Is Septerna, Inc. (NASDAQ:SEPN) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Septerna, Inc. at current levels.
First credible oral GPCR pipeline since the gold rush, with Novo Nordisk paying the bills and a 2026 Phase 2 readout that resets the floor.
Where SEPN is headed
Septerna sits in an unusual spot for a $1.4B clinical-stage biotech. Most GPCR companies died in the 2000s because the receptors were too floppy, too membrane-bound, too hard to drug with anything you could swallow. Septerna's native complex platform is the first credible answer to that problem in twenty years, and the proof point is not a slide deck, it is Novo Nordisk writing the cheques on the metabolic collaboration signed in 2024. Novo does not need help finding peptide GLP-1s. They need oral small molecules they cannot build themselves.
Read the full Compass Direction on SEPN
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $28.36).
See the full SEPN analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Septerna, Inc. (NASDAQ:SEPN) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Septerna, Inc. at current levels. First credible oral GPCR pipeline since the gold rush, with Novo Nordisk paying the bills and a 2026 Phase 2 readout that resets the floor.
What is SEPN's Compass Score?
Septerna, Inc. scores 82/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for SEPN?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the SEPN page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.